# COVID-19 Vaccine Effectiveness and Risk Factors of Booster Failure in 480,000 Patients with Diabetes Mellitus: A Population-Based Cohort Study

**Authors:** Maria Christina L. Oliveira, Daniella R. Martelli, Ana Cristina Simões e Silva, Cristiane S. Dias, Lilian M. Diniz, Enrico A. Colosimo, Clara C. Pinhati, Stella C. Galante, Fernanda N. Duelis, Laura E. Carvalho, Laura G. Coelho, Maria Eduarda T. Bernardes, Hercílio Martelli-Júnior, Fabrício Emanuel S. de Oliveira, Robert H. Mak, Eduardo A. Oliveira

PMC · DOI: 10.3390/microorganisms13050979 · Microorganisms · 2025-04-24

## TL;DR

This study shows that while COVID-19 vaccines are effective in reducing death among people with diabetes, their protection is lower when combined with other health issues or the omicron variant.

## Contribution

The study provides real-world evidence on vaccine effectiveness and booster failure risk in a large diabetic population.

## Key findings

- Vaccine effectiveness after a booster was similar for diabetic and non-diabetic patients without comorbidities.
- Booster effectiveness was reduced in diabetic patients with additional comorbidities.
- The omicron variant was the strongest factor associated with booster failure.

## Abstract

To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort of patients with diabetes mellitus (DM), we analyzed all >18-year-old patients with COVID-19 registered in a Brazilian nationwide surveillance database between February 2020 and February 2023. The primary outcome of interest was vaccine effectiveness against death, evaluated using multivariate logistic regression models. Among the 2,131,089 patients registered in the SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, patients with DM had a higher risk of death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For patients without comorbidities (72.7%, 95% CI, 70.5–74.7) and those with DM (73.4%, 95% CI, 68.2–76.7), vaccine effectiveness was similar after the booster dose. However, it was reduced in patients with DM associated with other comorbidities (60.5%; 95% CI, 57.5–63.2). The strongest factor associated with booster failure was the omicron variant (aOR = 27.8, 95% CI, 19.9–40.1). Our study revealed that COVID-19 vaccines provided robust protection against death in individuals with DM. However, our findings underscore the need to update vaccines and develop tailored strategies for individuals with diabetes, especially those with additional underlying conditions.

## Linked entities

- **Diseases:** diabetes mellitus (MONDO:0005015), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** Booster Failure (MESH:D051437), COVID-19 (MESH:D000086382), DM (MESH:D003920), death (MESH:D003643)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12114578/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12114578/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12114578/full.md

---
Source: https://tomesphere.com/paper/PMC12114578